Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...
pulmonologyadvisor7d
Chronic Cough Reduced Through Behavioral Cough Suppression Therapy
Behavioral cough suppression therapy may be effective in patients with refractory and unexplained chronic cough (RCC and UCC).
Medscape23h
Post-COVID Cough Linked to Neurological Dysfunction
Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.
Sacramento Bee10d
Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...
Yahoo Finance9d
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market Differentiated approach with demonstrated preclinical ...
Yahoo Finance14d
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
There are no approved therapies for the treatment of chronic cough in IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough affects approximately ...